Axsome Therapeutics (AXSM) Other financing activities (2016 - 2025)

Axsome Therapeutics has reported Other financing activities for 10 years, with the latest figure at $17.0 million in Q1 2025.

• Quarterly Other financing activities rose 581.13% year-over-year to $17.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $25.0 million (up 72.01% YoY) and the FY2023 annual result came in at $12.4 million, up 98.67% from the prior year.
• Other financing activities advanced to $17.0 million in Q1 2025 per AXSM's latest filing, from $2.5 million in the prior quarter.
• Over five years, Other financing activities peaked at $17.0 million in Q1 2025 and troughed at $176000.0 in Q2 2022.
• A 5-year average of $3.0 million and a median of $1.5 million in 2021 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2023: Other financing activities sank 90.49% in 2022, then surged 3632.95% in 2023.
• Over 5 years, Other financing activities stood at $1.1 million in 2021, then surged by 159.27% to $2.8 million in 2022, then sank by 59.53% to $1.1 million in 2023, then soared by 118.43% to $2.5 million in 2024, then soared by 581.13% to $17.0 million in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $17.0 million, $2.5 million, and $1.1 million for Q1 2025, Q1 2024, and Q4 2023 respectively.